Re: Radiopharmaceuticals and Breastfeeding

["JERRY ROSEN" <ROSEN@rso.radsafe.pitt.edu>]

> Date:          Tue, 27 Jun 95 18:09:01 -0500
> Reply-to:      radsafe@romulus.ehs.uiuc.edu
> From:          "Barry Siegel" <siegelb@mirlink.wustl.edu>
> To:            Multiple recipients of list <radsafe@romulus.ehs.uiuc.edu>
> Subject:       Radiopharmaceuticals and Breastfeeding

With respect to the Tl-201, I just received a copy of ICRP-68.  The 
Appendix in the back on Principles for Protection in Nuclear 
Medicine, recommends a minimum of three (3) week cessation of nursing following 
Tl-201 administration


_____________________________________
> The May 1995 issue of the European Journal of Nuclear Medicine (1995; 22: BP17)
>  contains a statement from the European Association for Nuclear Medicine
> (authors Harding LK, Bossuyt A, Pellet S, Reiners c, and Talbot JN) entitled
> "Recommendations for Nuclear Medicine Physicians Regarding Breastfeeding
> Mothers."  This succinct summary is quite useful, but contains one
> recommendation that may be overcautious.  Specifically, the article recommends
> that breastfeeding is contraindicated in women who receive Tl-201 chloride. 
> Several months ago, I was prompted to look into the available literature while
> obtaining measurements of breast milk activity in a breastfeeding patient who
> had received Tl-201.  The information I uncovered at that time (including that
> provided by Michael Stabin at Oak Ridge) suggested that interruption of
> breastfeeding for about 48 hours was sufficient with usual doses of Tl-201. 
> Does anyone know of specific data to the contrary?
> Barry A. Siegel, M.D.
> Division of Nuclear Medicine
> Mallinckrodt Institute of Radiology
> 510 S. Kingshighway Blvd.
> St. Louis, MO 63110
> PHONE:  (314) 362-2809
> FAX:  (314) 362-2806
> INTERNET:  siegelb@mirlink.wustl.edu
> 
>